Traders Purchase High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw unusually large options trading on Tuesday. Traders acquired 27,298 call options on the company. This is an increase of 82% compared to the typical volume of 14,998 call options.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the completion of the sale, the insider directly owned 10,914 shares of the company’s stock, valued at $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric A. Hughes sold 9,533 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $301,910.11. Following the transaction, the insider owned 107,711 shares in the company, valued at $3,411,207.37. This represents a 8.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 920,901 shares of company stock worth $30,056,789 over the last quarter. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after buying an additional 7,255,083 shares during the period. Phoenix Financial Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares during the period. Menora Mivtachim Holdings LTD. boosted its holdings in Teva Pharmaceutical Industries by 1.1% in the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after acquiring an additional 427,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 18.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after acquiring an additional 5,917,423 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares during the period. Institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Barclays boosted their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Scotiabank raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $1.77 during trading on Tuesday, hitting $30.12. The company had a trading volume of 6,555,325 shares, compared to its average volume of 9,099,524. The company has a fifty day moving average price of $32.26 and a two-hundred day moving average price of $27.54. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a market cap of $34.63 billion, a P/E ratio of 25.10, a P/E/G ratio of 9.62 and a beta of 0.72. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business’s revenue was up 11.4% on a year-over-year basis. During the same period last year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.